Article
Biochemistry & Molecular Biology
YuanPu Meng, Bo Zhou, Zhe Pei, Ye Chen, Dongmin Chang
Summary: This study investigated the biological properties and mechanisms of growth hormone receptor (GHR) in gastric cancer cells. It was found that GHR can translocate into the nuclei of gastric cancer cells and is closely related to cell proliferation. The GHR inhibitor, pegvisomant, was shown to inhibit both cell proliferation and nuclear localization of GHR, suggesting its potential as a dual-effect antagonist. These findings highlight GHR as a potential target for gastric cancer treatment.
BIOCHEMISTRY AND CELL BIOLOGY
(2022)
Article
Endocrinology & Metabolism
Aline Franco da Rocha, Paulo Sergio Pereira Junior, Gabriela Simonetti Calefi, Guilherme Figueiredo Marquezine, Helena Kaminami Morimoto, Tania Longo Mazzuco, Eliana Cotta de Faria, Mariana Ragassi Urbano, Alexandre Jose Faria Carrilho
Summary: The study investigated the role of growth hormone in promoting ketogenesis in patients treated with empagliflozin. Empagliflozin treatment decreased glucose and free fatty acid concentrations, while increasing beta-hydroxybutyrate levels.
Article
Endocrinology & Metabolism
Sabrina Chiloiro, Antonio Bianchi, Antonella Giampietro, Alfredo Pontecorvi, Gerald Raverot, Laura De Marinis
Summary: This review provides an overview of the second-line therapies for acromegaly, summarizing the evidence on clinical, molecular, and morphological aspects that can predict the response to these treatments and advocating for a patient-tailored therapeutic approach in clinical practice.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Medicine, General & Internal
Soo -Ho Chung, Hae-Hyeog Lee, Yeon-Suk Kim, Kisung Song, Tae-Hee Kim
Summary: This study confirms that combined treatment with DHA and triacsin C can significantly induce apoptosis in endometrial cancer cells, activating multiple apoptotic pathways through mitochondrial and extrinsic pathways. Further research into the apoptotic mechanisms of DHA and triacsin C may lead to the development of therapeutic strategies for endometrial cancer.
ARCHIVES OF MEDICAL SCIENCE
(2023)
Review
Medicine, General & Internal
Tomohito Tanaka, Ruri Nishie, Shoko Ueda, Shunsuke Miyamoto, Sousuke Hashida, Hiromi Konishi, Shinichi Terada, Yuhei Kogata, Hiroshi Sasaki, Satoshi Tsunetoh, Kohei Taniguchi, Kazumasa Komura, Masahide Ohmichi
Summary: This review identified and verified articles on endometrial cancer patient-derived xenografts (EC-PDXs). The results showed that EC-PDXs are promising tools for translational research as they closely resemble the features of tumors in patients and retain molecular and histological features of the disease.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Medicine, General & Internal
Emma J. Crosbie, Sarah J. Kitson, Jessica N. McAlpine, Asima Mukhopadhyay, Melanie E. Powell, Naveena Singh
Summary: Endometrial cancer is the most common gynaecological cancer in high income countries, with a global rise in incidence. Obesity is the major underlying cause, posing challenges for diagnosis and treatment. Early presentation with postmenopausal bleeding ensures cure, but advanced cases have poor prognosis. Minimally invasive surgical staging and targeted chemotherapeutic strategies are important advances.
Article
Genetics & Heredity
Vanessa F. Bonazzi, Olga Kondrashova, Deborah Smith, Katia Nones, Asmerom T. Sengal, Robert Ju, Leisl M. Packer, Lambros T. Koufariotis, Stephen H. Kazakoff, Aimee L. Davidson, Priya Ramarao-Milne, Vanessa Lakis, Felicity Newell, Rebecca Rogers, Claire Davies, James Nicklin, Andrea Garrett, Naven Chetty, Lewis Perrin, John Pearson, Ann-Marie Patch, Nicola Waddell, Pamela M. Pollock
Summary: Endometrial cancer comprises four molecular subtypes with differing etiology, prognoses, and responses to chemotherapy. Patient-derived xenograft models have been successfully generated and showed sensitivity to PARP inhibitor in copy number high molecular subtype; however, deeper and more durable responses will likely require combination of PARPi with other agents.
Article
Oncology
Ahmed O. Kaseb, Abedul Haque, Deeksha Vishwamitra, Manal M. Hassan, Lianchun Xiao, Bhawana George, Vishal Sahu, Yehia I. Mohamed, Roberto Carmagnani Pestana, Jamie Lynne Lombardo, Rony Avritscher, James C. Yao, Robert A. Wolff, Asif Rashid, Jeffrey S. Morris, Hesham M. Amin
Summary: Hepatocellular carcinoma is an aggressive neoplasm with limited systemic therapy options. This study suggests that growth hormone receptor (GHR) signaling could be a potential therapeutic target for HCC, and pegvisomant may be an effective systemic therapy for this aggressive cancer.
FRONTIERS IN ONCOLOGY
(2022)
Review
Cell Biology
Gunter Emons, Carsten Gruendker
Summary: Endometrial cancer expresses GnRH and its receptor, which can regulate proliferation, the cell cycle, and apoptosis. GnRH agonists are used in fertility preserving therapy for early EC, but show limited activity in advanced or recurrent EC. Further clinical trials exploring the GnRH-system in EC may be beneficial.
Article
Biochemistry & Molecular Biology
Yunfeng Song, Mengfei Wang, Huan Tong, Yuan Tan, Xiang Hu, Kai Wang, Xiaoping Wan
Summary: Plasma exosomes containing LGALS3BP contribute to the growth and angiogenesis of endometrial cancer during disease progression, providing a novel perspective on diagnosis and prognosis.
Article
Endocrinology & Metabolism
Thierry Brue, Philippe Chanson, Patrice Rodien, Brigitte Delemer, Delphine Drui, Lucile Marie, Laurene Juban, Lara Salvi, Robin Henocque, Gerald Raverot
Summary: The study aimed to estimate the cost-utility of second-line pharmacological treatments in acromegaly patients.
The incremental cost-utility ratios for pasireotide, pegvisomant, and pegvisomant + FGSA were estimated, showing pasireotide to be the least cost-efficient treatment option.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Beatriz Villafranca-Magdalena, Carina Masferrer-Ferragutcasas, Carlos Lopez-Gil, Eva Coll-de la Rubia, Marta Rebull, Genis Parra, Angel Garcia, Armando Reques, Silvia Cabrera, Eva Colas, Antonio Gil-Moreno, Cristian P. Moiola
Summary: Endometrial cancer is the second most common gynecological cancer worldwide, and limited treatment options are available for high-risk or recurrent cases. This study proposes patient-derived xenograft models to closely mimic the disease and demonstrates their ability to recapitulate histological and molecular features. Thorough characterization of preclinical models is crucial for improving the success rate of personalized medicine drug-screening assays.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Endocrinology & Metabolism
Bradley S. Miller, Joanne C. Blair, Michael Hojby Rasmussen, Aristides Maniatis, Jun Mori, Volker Boettcher, Ho-Seong Kim, Rikke Beck Bang, Michel Polak, Reiko Horikawa
Summary: This study evaluated the efficacy and tolerability of somapacitan in children with growth hormone deficiency (GHD) for 2 years and after switching from daily growth hormone treatment. The results showed that somapacitan was effective and well-tolerated during the 2-year period, and patients and caregivers preferred once-weekly somapacitan treatment.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Aristides K. Maniatis, Samuel J. Casella, Ulhas M. Nadgir, Paul L. Hofman, Paul Saenger, Elena D. Chertock, Elena M. Aghajanova, Maria Korpal-Szczyrska, Elpis Vlachopapadopoulou, Oleg Malievskiy, Tetyana Chaychenko, Marco Cappa, Wenjie Song, Meng Mao, Per Holse Mygind, Alden R. Smith, Steven Chessler, Allison S. Komirenko, Michael Beckert, Aimee D. Shu, Paul S. Thornton
Summary: This trial aims to assess the long-term safety and efficacy of lonapegsomatropin in children with growth hormone deficiency. The results show that lonapegsomatropin treatment can continue to improve height without causing excessive advancement of bone age. Patients using the TransCon hGH Auto-Injector reported fewer local tolerability reactions.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Oncology
Laura Paleari, Silvia Pesce, Mariangela Rutigliani, Marco Greppi, Valentina Obino, Franco Gorlero, Valerio Gaetano Vellone, Emanuela Marcenaro
Summary: Endometrial cancer is the most common cancer in the female genital tract, with management focused on understanding its hormonal nature, molecular and histopathological assessment, and potential immunotherapy approaches. The increasing incidence of EC due to risk factors like aging and obesity highlights the need for personalized treatment strategies.
Article
Oncology
Tarek M. A. Abdel-Fatah, Reuben J. Broom, Jun Lu, Paul M. Moseley, Baiqu Huang, Lili Li, Suling Liu, Longxin Chen, Runlin Z. Ma, Wenming Cao, Xiaojia Wang, Yan Li, Jo K. Perry, Mohammed Aleskandarany, Christopher C. Nolan, Emad A. Rakha, Peter E. Lobie, Stephen Y. T. Chan, Ian O. Ellis, Le-Ann Hwang, David P. Lane, Andrew R. Green, Dong-Xu Liu
BRITISH JOURNAL OF CANCER
(2019)
Article
Biotechnology & Applied Microbiology
Elsie C. Jacobson, Ralph S. Grand, Jo K. Perry, Mark H. Vickers, Ada L. Olins, Donald E. Olins, Justin M. O'Sullivan
Article
Genetics & Heredity
Elsie C. Jacobson, Lekha Jain, Mark H. Vickers, Ada L. Olins, Donald E. Olins, Jo K. Perry, Justin M. O'Sullivan
G3-GENES GENOMES GENETICS
(2019)
Article
Biochemical Research Methods
Yue Wang, Ries J. Langley, Kyle Tamshen, Stephen M. Jamieson, Man Lu, Heather D. Maynard, Jo K. Perry
BIOCONJUGATE CHEMISTRY
(2020)
Article
Biochemical Research Methods
Kyle Tamshen, Yue Wang, Stephen M. F. Jamieson, Jo K. Perry, Heather D. Maynard
BIOCONJUGATE CHEMISTRY
(2020)
Article
Clinical Neurology
William Schierding, Sophie Farrow, Tayaza Fadason, Oscar E. E. Graham, Toni L. Pitcher, Sara Qubisi, Alan J. Davidson, Jo K. Perry, Tim J. Anderson, Martin A. Kennedy, Antony Cooper, Justin M. O'Sullivan
MOVEMENT DISORDERS
(2020)
Editorial Material
Endocrinology & Metabolism
Mark H. Vickers, Jo K. Perry
Article
Biochemistry & Molecular Biology
Yue Wang, Ries J. Langley, Kyle Tamshen, Julia Harms, Martin J. Middleditch, Heather D. Maynard, Stephen M. F. Jamieson, Jo K. Perry
Summary: The study successfully generated a novel PEGylated GHR antagonist by site-specific attachment of mPEG maleimide at an introduced cysteine residue, effectively reducing serum IGF-I levels in vivo.
Article
Biology
Daniel Ho, Denis M. Nyaga, William Schierding, Richard Saffery, Jo K. Perry, John A. Taylor, Mark H. Vickers, Andreas W. Kempa-Liehr, Justin M. O'Sullivan
Summary: A machine learning approach was developed to rank tissue-specific gene regulatory effects for T1D SNPs, identifying an eQTL associated with changes to AP4B1-AS1 transcript levels in lung tissue as making the largest gene regulatory contribution to T1D risk. The strongest tissue-specific eQTL effects were observed in lung tissue, potentially explaining associations between respiratory infections and risk of islet autoantibody seroconversion in young children.
COMMUNICATIONS BIOLOGY
(2021)
Review
Oncology
Michael Pudjihartono, Jo K. Perry, Cris Print, Justin M. O'Sullivan, William Schierding
Summary: This study reviews the research on non-coding mutations and emphasizes the importance of interpreting and prioritizing different regulatory data types to deepen our understanding of novel mechanisms driving cancer.
CLINICAL EPIGENETICS
(2022)
Review
Oncology
Yue Wang, Stephen M. F. Jamieson, Jo K. Perry
Summary: Published research supports the role of growth hormone in cancer, leading to increasing interest in targeting growth hormone in oncology. Growth hormone receptor antagonists have shown efficacy in xenograft studies as single agents or in combination with other anticancer therapies. However, there are challenges in using growth hormone receptor antagonists in preclinical models, such as identifying predictive biomarkers for selecting patients and monitoring drug efficacy.
ENDOCRINE-RELATED CANCER
(2023)
Article
Cell Biology
Lekha Jain, Mark H. Vickers, Bincy Jacob, Martin J. Middleditch, Daria A. Chudakova, Austen R. D. Ganley, Justin M. O'Sullivan, Jo K. Perry
Summary: Growth hormone (GH) activates downstream signalling by binding to its cell-surface receptor, the GH receptor (GHR). However, nuclear localization of GHR has been observed and linked to increased cancer cell proliferation. In this study, the authors investigated the functional implications of GHR nuclear translocation in two cancer cell lines and identified potential interactions with chromatin factors. The findings suggest that GHR nuclear translocation might mediate GH actions by influencing downstream transcriptional programs.
JOURNAL OF CELL COMMUNICATION AND SIGNALING
(2023)
Review
Biochemistry & Molecular Biology
Man Lu, Jack U. Flanagan, Ries J. Langley, Michael P. Hay, Jo K. Perry
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2019)
Review
Public, Environmental & Occupational Health
E. Jacobson, M. H. Vickers, J. K. Perry, J. M. O'Sullivan
JOURNAL OF DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE
(2018)
Review
Endocrinology & Metabolism
Shutan Liao, Mark H. Vickers, Joanna L. Stanley, Philip N. Baker, Jo K. Perry
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.